{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:51:02Z","timestamp":1786125062446,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Hearing response following an osteodural decompression of the internal auditory canal (IAC) is controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the course of auditory brainstem responses (ABRs) and the early hearing response during the first year following IAC decompression for small to medium-sized vestibular schwannomas occurring in neurofibromatosis type 2 (NF2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Retrospective chart review of middle fossa craniotomy for IAC osteodural decompression in NF2-related vestibular schwannomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twelve NF2 patients were operated on from 2011 to 2016 for IAC decompression. All had NF2 according to the Manchester criteria. All had a progressive change of their ABRs documented from the diagnosis of NF2 over a mean period of 6.25 [0.36;10.9] yr. Treatment was proposed to stop hearing progression based on the speech discrimination scores (SDSs; n\u00a0=\u00a04) or for hearing maintenance (n\u00a0=\u00a08). In patients with prior hearing progression, hearing responses were observed in 3 of the 4 patients during the first year. One patient kept on progressing. In the hearing maintenance group, the SDSs remained stable. SDSs improved from 85% [20-100] to 92.5% [60-100] on average (n\u00a0=\u00a012) and from 55% [20-80] to 77.5% [50-100] in the hearing progression group (n\u00a0=\u00a04). ABRs improved in 4 patients following decompression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>IAC decompression allows early objective hearing responses in select patients. We suggest that the procedure should be offered to patients with hearing progression based on their SDSs and\/or associated progressive increases in their wave III and V latencies on ABRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyz057","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T16:28:08Z","timestamp":1551284888000},"page":"E560-E567","source":"Crossref","is-referenced-by-count":3,"title":["Hearing Response Following Internal Auditory Canal Decompression in Neurofibromatosis Type 2"],"prefix":"10.1227","volume":"85","author":[{"given":"Nicolas-Xavier","family":"Bonne","sequence":"first","affiliation":[{"name":"CHU Lille, Otologie et Otoneurologie, Universit\u00e9 de Lille, Inserm U1008, Controlled Drug Delivery Systems and Biomaterials, Lille, France"},{"name":"Universit\u00e9 de Lille, Inserm U1192, Prot\u00e9omique R\u00e9ponse Inflamatoire Spectrom\u00e9trie de Masse, PRISM, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Risoud","sequence":"additional","affiliation":[{"name":"CHU Lille, Otologie et Otoneurologie, Universit\u00e9 de Lille, Inserm U1008, Controlled Drug Delivery Systems and Biomaterials, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoa","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Georgetown University Hospital, NC, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Lemesre","sequence":"additional","affiliation":[{"name":"CHU Lille, Otologie et Otoneurologie, Universit\u00e9 de Lille, Inserm U1008, Controlled Drug Delivery Systems and Biomaterials, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Aboukais","sequence":"additional","affiliation":[{"name":"CHU Lille, Department of General and Stereotaxic Neurosurgery, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lille, Inserm U1192, Prot\u00e9omique R\u00e9ponse Inflamatoire Spectrom\u00e9trie de Masse, PRISM, Lille, France"},{"name":"CHU Lille, Department of General and Stereotaxic Neurosurgery, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Dubrulle","sequence":"additional","affiliation":[{"name":"CHU Lille, Department of Radiology, H\u00f4pital Huriez, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baroncini","sequence":"additional","affiliation":[{"name":"CHU Lille, Department of General and Stereotaxic Neurosurgery, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Lejeune","sequence":"additional","affiliation":[{"name":"CHU Lille, Department of General and Stereotaxic Neurosurgery, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vincent","sequence":"additional","affiliation":[{"name":"CHU Lille, Otologie et Otoneurologie, Universit\u00e9 de Lille, Inserm U1008, Controlled Drug Delivery Systems and Biomaterials, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"issue":"4","key":"bib1-20231011","first-page":"450","article-title":"Audiometric findings in patients with acoustic neuroma","volume":"21","author":"Harner","year":"2000","journal-title":"Am J Otol"},{"issue":"2","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00405-012-1954-2","article-title":"Audiological correlates of tumor parameters in acoustic neuromas","volume":"270","author":"Tutar","year":"2013","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"9","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/MAO.0b013e3182a1a8b4","article-title":"English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2","volume":"34","author":"Tysome","year":"2013","journal-title":"Otol Neurotol"},{"issue":"9","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1288\/00005537-199009000-00007","article-title":"Middle fossa decompression of the internal auditory canal in acoustic neuroma surgery: a therapeutic alternative","volume":"100","author":"Gadre","year":"1990","journal-title":"Laryngoscope"},{"issue":"6","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/MAO.0b013e3182267eb7","article-title":"Middle fossa decompression for hearing preservation: a review of institutional results and indications","volume":"32","author":"Slattery","year":"2011","journal-title":"Otol Neurotol"},{"key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1227\/NEU.0000000000001125","article-title":"Internal auditory canal decompression for hearing maintenance in neurofibromatosis type 2 patients","volume":"79","author":"Bernardeschi","year":"2016","journal-title":"Neurosurgery"},{"issue":"4","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"2","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J Neurooncol"},{"issue":"10","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/lary.25976","article-title":"Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: a volumetric consideration","volume":"126","author":"Picry","year":"2016","journal-title":"Laryngoscope"},{"issue":"21 Suppl 1","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/01.wnl.0000435746.02780.f6","article-title":"Hearing and facial function outcomes for neurofibromatosis 2 clinical trials","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol"},{"issue":"2","key":"bib13-20231011","first-page":"274","article-title":"Early proactive management of vestibular schwannomas in neurofibromatosis type 2","volume":"49","author":"Brackmann","year":"2001","journal-title":"Neurosurgery"},{"issue":"9","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/MAO.0b013e3182355855","article-title":"Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2","volume":"32","author":"Friedman","year":"2011","journal-title":"Otol Neurotol"},{"issue":"4 Suppl","key":"bib15-20231011","first-page":"255","article-title":"Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients","volume":"106","author":"Slattery","year":"2007","journal-title":"J Neurosurg"},{"issue":"5","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/MAO.0b013e318254ede3","article-title":"Middle fossa approach for resection of vestibular schwannoma: impact of cochlear fossa extension and auditory monitoring on hearing preservation","volume":"33","author":"Vincent","year":"2012","journal-title":"Otol Neurotol"},{"issue":"7","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/MAO.0b013e3181e8fc3f","article-title":"Fundal fluid as a predictor of hearing preservation in the middle cranial fossa approach for vestibular schwannoma","volume":"31","author":"Goddard","year":"2010","journal-title":"Otol Neurotol"},{"issue":"9","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/MAO.0b013e3181f7ab47","article-title":"Hearing preservation in retrosigmoid approach of small vestibular schwannomas: prognostic value of the degree of internal auditory canal filling","volume":"31","author":"Tringali","year":"2010","journal-title":"Otol Neurotol"},{"issue":"2","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1148\/radiology.215.2.r00ma20458","article-title":"Cochlear fossa enhancement at MR evaluation of vestibular schwannoma: correlation with success at hearing-preservation surgery","volume":"215","author":"Dubrulle","year":"2000","journal-title":"Radiology"},{"issue":"9","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MAO.0000000000000494","article-title":"Neurofibromatosis 2 invasion of the internal auditory canal wall: clinical significance","volume":"35","author":"Doherty","year":"2014","journal-title":"Otol Neurotol"},{"key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/lary.25859","article-title":"Infrared videoangiographic assessment of cochlear nerve vasculature during middle fossa surgery","volume":"126","author":"Bonne","year":"2016","journal-title":"Laryngoscope"},{"issue":"3","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3171\/jns.1994.80.3.0541","article-title":"Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases","volume":"80","author":"Jaaskelainen","year":"1994","journal-title":"J Neurosurg"},{"issue":"9","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"e46132","DOI":"10.1371\/journal.pone.0046132","article-title":"Mechanisms of hearing loss in neurofibromatosis type 2","volume":"7","author":"Asthagiri","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/000348947108000105","article-title":"Inner ear fluid proteins in acoustic neuroma, Meniere's disease and otosclerosis","volume":"80","author":"Silverstein","year":"1971","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1021\/pr200346q","article-title":"Proteome of human perilymph","volume":"10","author":"Lysaght","year":"2011","journal-title":"J Proteome Res"},{"issue":"5","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/acs.jproteome.6b00986","article-title":"Proteome Analysis of human perilymph using intraoperative sampling method","volume":"16","author":"Schmitt","year":"2017","journal-title":"J Proteome Res."},{"issue":"2","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MAO.0000000000000191","article-title":"Hearing preservation and vestibular schwannoma: intracochlear FLAIR signal relates to hearing level","volume":"35","author":"Miller","year":"2014","journal-title":"Otol Neurotol"},{"issue":"5","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1177\/0194599816630544","article-title":"Quantitative proteomics of vestibular schwannoma cerebrospinal fluid: a pilot study","volume":"154","author":"Kazemizadeh","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archotol.130.5.518","article-title":"Surface microstructure of the perilymphatic space: implications for cochlear implants and cell- or drug-based therapies","volume":"130","author":"Shepherd","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"11","key":"bib30-20231011","first-page":"1498","article-title":"Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells","volume":"18","author":"Soares","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00016489.1992.11665411","article-title":"Preservation of hearing in bilateral acoustic neurinomas by deliberate partial resection","volume":"112","author":"Wigand","year":"1992","journal-title":"Acta Otolaryngol"},{"issue":"(suppl 1)","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000380746","article-title":"Quality of life and auditory performance in adults with asymmetric hearing loss","volume":"20","author":"Vannson","year":"2015","journal-title":"Audiol Neurootol"},{"issue":"5","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/archotol.130.5.524","article-title":"Speech-language and educational consequences of unilateral hearing loss in children","volume":"130","author":"Lieu","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"6","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1542\/peds.2009-2448","article-title":"Unilateral hearing loss is associated with worse speech-language scores in children","volume":"125","author":"Lieu","year":"2010","journal-title":"Pediatrics"},{"issue":"9","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/lary.23454","article-title":"Longitudinal study of children with unilateral hearing loss","volume":"122","author":"Lieu","year":"2012","journal-title":"Laryngoscope"},{"issue":"2","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/14992020400050015","article-title":"Interaural asymmetry of hearing loss, Speech, Spatial and Qualities of Hearing Scale (SSQ) disabilities, and handicap","volume":"43","author":"Noble","year":"2004","journal-title":"Int J Audiol"},{"issue":"4","key":"bib37-20231011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MAO.0000000000001756","article-title":"Right ear advantage of speech audiometry in single-sided deafness","volume":"39","author":"Wettstein","year":"2018","journal-title":"Otol Neurotol"},{"issue":"5","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1682\/JRRD.2007.08.0120","article-title":"Restoring hearing symmetry with two cochlear implants or one cochlear implant and a contralateral hearing aid","volume":"45","author":"Firszt","year":"2008","journal-title":"J Rehabil Res Dev"},{"issue":"7","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3766\/jaaa.17034","article-title":"An Evaluation of the World Health Organization and American Medical Association ratings of hearing impairment and simulated single-sided deafness","volume":"29","author":"Vermiglio","year":"2018","journal-title":"J Am Acad Audiol"},{"issue":"10","key":"bib40-20231011","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","article-title":"Genetic Severity Score predicts clinical phenotype in NF2","volume":"54","author":"Halliday","year":"2017","journal-title":"J Med Genet"},{"issue":"4","key":"bib41-20231011","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","article-title":"Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity","volume":"52","author":"Parry","year":"1994","journal-title":"Am J Med Genet"},{"issue":"3","key":"bib1a-20231011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1227\/NEU.0000000000001125","article-title":"Internal auditory canal decompression for hearing maintenance in neurofibromatosis type 2 patients","volume":"79","author":"Bernardeschi","year":"2016","journal-title":"Neurosurgery"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyz057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:42Z","timestamp":1786121382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyz057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyz057","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}